Letters, Statements & Analysis
AMCP communicates the importance of managed care pharmacy by collaborating with members to provide comments, analysis, and testimony to Congress and federal and state agencies on the impact of proposed regulations and laws on managed care pharmacy and patients.
The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to provide comments in response to the request for comments titled “Administering the HatchWaxman Amendments: Ensuring a Balance Between Innovation and Access [Docket No. FDA–2017–N–3615]” as published in the Federal Register on June 22, 2017.
The Academy of Managed Care Pharmacy (AMCP) thanks the Centers for Medicare and Medicaid Services (CMS) for the opportunity to provide comments in response to the solicitation of public comments on biosimilars included in the proposed rule “Medicare Program; Revisions to Payment Policies under the Physician Fee Schedule and Other Revisions to Part B for CY 2018 [Docket No. CMS-1676-P]” as published in the Federal Register on July 21, 2017.
AMCP joins a coalition of over 35 health care stakeholders committed to aligning 42 CFR part 2 (part 2) with HIPAA to allow appropriate access to patient information that is essential for providing whole-person care.
The Academy of Managed Care Pharmacy (AMCP) thanks the Institute of Clinical and Economic Review (ICER) for the opportunity to provide comments on the “Potential Topics for Review in 2018” released on July 26, 2017. AMCP applauds ICER for considering new and emerging therapies, as well as incorporating public feedback, into the development of a robust review agenda for 2018.
The Academy of Managed Care Pharmacy (AMCP) thanks the International Society for Pharmacoeonomics and Outcomes Research (ISPOR) for the opportunity to comment on the Draft Special Task Force Report “A Health Economics Approach to US Value Assessment Frameworks” as updated on July 7, 2017.
The Academy of Managed Care Pharmacy thanks the Centers for Medicare and Medicaid Services (CMS) for the opportunity to comment on the Proposed Rule, Medicare Program; CY 2018 Updates to the Quality Payment Program (the Proposed Rule).
AMCP supports a coalition of over 20 health care stakeholders committed to aligning 42 CFR Part 2 (Part 2) with HIPAA to allow appropriate access to patient information that is essential for providing whole-person care.
On behalf of the Academy of Managed Care Pharmacy (AMCP), I wanted to take this opportunity to express our strong support for the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (H.R. 2212), bipartisan legislation to increase competition and patient access to safe and affordable generic and biosimilar medicines.
The Friends of the National Quality Forum (NQF) strongly urge you to support continuing the currently authorized $30 million in annual Medicare funding for NQF and quality and performance measurement. NQF’s work is vital to advancing our national commitment to safer, more effective care.
The undersigned organizations commend you for your leadership in introducing H.R. 2026 – The Pharmaceutical Information Exchange (PIE) Act of 2017 which will improve patient access to emerging medication therapies and devices by codifying a safe harbor for certain health care economic and scientific information communications between biopharmaceutical and medical device manufacturers and population health decision makers.
The Academy of Managed Care Pharmacy (AMCP) thanks the Institute of Clinical and Economic Review (ICER) for the opportunity to provide comments on the draft evidence report titled “Abuse Deterrent Formulations (ADFs) of Opioids: Effectiveness and Value” released on May 5, 2017.
The Academy of Managed Care Pharmacy (AMCP) is writing to express concerns with specific provisions of Senate Bill 4788 regarding the regulation of biological products and the substitution of interchangeable biological products when dispensed by pharmacists.
